Juan Qin

Juan Qin

Auto-generated profile, based on publicly available information

Juan Qin

Center of Interventional Radiology and Vascular Surgery Department of Radiology Zhongda Hospital Medical School Southeast University Nanjing China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2022 in Acta Biomaterialia
Verified
Journal Article
Closed access
LLLin-Lin Liu
Lin-Lin Liu
JQJuan Qin
Juan Qin
CZChu Hui Zeng
Chu Hui Zeng
RDRui-Jie Du
Rui-Jie Du
TPTao Pan
Tao Pan
GTGao-Jun Teng
Gao-Jun Teng

18 December 2024 in Biomaterials
Verified
Journal Article
Closed access
LZLei Zhang
Lei Zhang
DWDuo Wang
Duo Wang
LZLin-Zhu Zhang
Lin-Zhu Zhang
WYWei-Hao Yang
Wei-Hao Yang
CYChao Yu
Chao Yu
GTGao-Jun Teng
Gao-Jun Teng

1 September 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
LZLin-Zhu Zhang
Lin-Zhu Zhang
RDRui-Jie Du
Rui-Jie Du
DWDuo Wang
Duo Wang
JQJuan Qin
Juan Qin
CYChao Yu
Chao Yu
HZHai-Dong Zhu
Hai-Dong Zhu
With the in-depth knowledge of the pathological and physiological characteristics of the intestinal barrier–portal vein/intestinal lymphatic vessels–systemic circulation axis, oral targeted drug delivery is frequently being renewed. With many advantages, such as high safety, convenient administration, and good patient compliance, many researchers have begun to explore targeted drug delivery from intravenous injections to oral administration. Over the past few decades, the fields of materials science and nanomedicine have produced various drug delivery platforms that hold great potential in overcoming the multiple barriers associated with oral drug delivery. However, the oral transport of particles into the systemic circulation is extremely difficult due to immune rejection and biochemical invasion in the intestine, which limits absorption and entry into the bloodstream. The feasibility of the oral delivery of targeted drugs to sites outside the gastrointestinal tract (GIT) is unknown. This article reviews the biological barriers to drug absorption, the in vivo fate and transport mechanisms of drug carriers, the theoretical basis for oral administration, and the impact of carrier structural evolution on oral administration to achieve this goal. Finally, this article reviews the characteristics of different nano-delivery systems that can enhance the bioavailability of oral therapeutics and highlights their applications in the efficient creation of oral anticancer nanomedicines.

27 September 2026 in Advanced Science
Verified
Journal Article
Open access
YLYi‐Ming Liu
Yi‐Ming Liu
JQJuan Qin
Juan Qin
SWSi‐Yuan Wu
Si‐Yuan Wu
XZXue‐Zhen Zhu
Xue‐Zhen Zhu
YCYun‐Fei Cai
Yun‐Fei Cai
HZHai-Dong Zhu
Hai-Dong Zhu
Microwave ablation (MWA) for large hepatocellular carcinoma (HCC) is frequently compromised by non‐uniform thermal distribution and immunosuppressive niche formation. To address these challenges, we engineered an injectable bimodal nanodepot (TCPD) via catalytic crosslinking of dopamine‐modified hyaluronic acid by microwave thermal converter cesium‐doped Prussian blue, enabling co‐delivery of glutaminase 1 inhibitor Telaglenastat and sonosensitizer Chlorin e6. Under combined MWA and ultrasound irradiation, TCPD nanodepot disrupts cellular antioxidant defenses and bioenergetic pathways through glutaminolysis‐TCA cycle blockade, metabolically sensitizing large tumors to spatially complementary sono‐thermal ablation and enabling complete treatment coverage. This multimodal intervention induces multiple subcellular stresses, including mitochondrial and endoplasmic reticulum dysfunction, genotoxicity, and NAD + depletion, which converge to facilitate PANoptosome assembly and immunogenic PANoptosis while activating the cGAS‐STING pathway. Subsequent release of damage‐associated molecular patterns and immunoregulatory cytokines promotes dendritic cell maturation, M1 macrophage polarization, and T lymphocyte infiltration, ultimately reprogramming the immunosuppressive microenvironment toward an immune‑activated niche. Integration with anti‐PD‐1 therapy further reinvigorates cytotoxic T lymphocytes and establishes antitumor immune memory to suppress tumor progression and metastasis, offering a multimodal therapeutic strategy for large HCC.